...
首页> 外文期刊>Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society >Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community
【24h】

Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community

机译:伤害治疗临床终点与FDA批准相关的临床疗效和患者价值的鉴定及内容验证。 第1部分。伤口护理社区的调查

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Wounds that exhibit delayed healing add extraordinary clinical, economic, and personal burdens to patients, as well as to increasing financial costs to health systems. New interventions designed to ease such burdens for patients with cancer, renal, or ophthalmologic conditions are often cleared for approval by the U.S. Food and Drug Administration (FDA) using multiple endpoints but the requirement of complete healing as a primary endpoint for wound products impedes FDA clearance of interventions that can provide other clinical or patient-centered benefits for persons with wounds. A multidisciplinary group of wound experts undertook an initiative, in collaboration with the FDA, to identify and content validate supporting FDA criteria for qualifying wound endpoints relevant to clinical practice (CP) and patient-centered outcomes (PCO) as primary outcomes in clinical trials. As part of the initiative, a research study was conducted involving 628 multidisciplinary expert wound clinicians and researchers from 4 different groups: the interdisciplinary core advisory team; attendees of the Spring 2015 Symposium on Advanced Wound Care (SAWC); clinicians employed by a national network of specialty clinics focused on comprehensive wound care; and Association for the Advancement of Wound Care (AAWC) and Wound Healing Society (WHS) members who had not previously completed the survey. The online survey assessed 28 literature-based wound care endpoints for their relevance and importance to clinical practice and clinical research. Fifteen of the endpoints were evaluated for their relevance to improving quality of life. Twenty-two endpoints had content validity indexes (CVI) >= 0.75, and 15 were selected as meriting potential inclusion as additional endpoints for FDA approval of future wound care interventions. This study represents an important first step in identifying and validating new measurable wound care endpoints for clinical research and practice and for regulatory evaluation.
机译:表现出延迟愈合的伤口为患者添加了非凡的临床,经济和个人负担,以及增加卫生系统的财务费用。旨在缓解癌症,肾病或眼科病症患者的新的干预措施通常被美国食品和药物管理局(FDA)批准使用多个终点,但完全愈合作为伤口产品的主要终点的要求阻碍了FDA可以为伤口的人提供其他临床或患者以患者为中心的益处的干预措施。多学科伤口专家组织倡议于与FDA合作进行倡议,以识别和内容支持与临床实践(CP)和患者以患者为中心的结果(PCO)为临床试验中的主要结果的验证FDA标准。作为该倡议的一部分,进行了一项研究研究,涉及628名多学科专家伤口临床医生和研究人员,来自4个不同的群体:跨学科核心咨询团队; 2015年春季与高级伤口护理研讨会(SAWC)的与会者;临床医生专注于综合伤口护理的国家专业诊所网络;和伤口护理(aawc)和伤口治疗会(whs)伤害治疗协会(whs)的协会,他们之前没有完成调查。在线调查评估了28个文学的伤口护理终点,以其对临床实践和临床研究的相关性和重要性。评估十五个终点,以提高生活质量的相关性。二十二个端点的内容有效性指数(CVI)> = 0.75,并选择了15个作为补偿潜在包容,作为FDA未来伤害干预措施的FDA批准的额外终点。本研究代表了鉴定和验证新可衡量的伤口护理终点,用于临床研究和实践以及监管评估的重要阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号